Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects

References

1. 1.↵
   1. Chandran V,
   2. Cook RJ,
   3. Edwin J, et al

   . Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology 2010;49:1399-405.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Moll JM,
   2. Wright V

   . Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Kane D,
   2. Stafford L,
   3. Bresnihan B,
   4. FitzGerald O

   . A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003;42:1460-8.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Poole CD,
   2. Lebmeier M,
   3. Ara R,
   4. Rafia R,
   5. Currie CJ

   . Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology 2010;49:1949-56.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Gladman D,
   2. Rigby W,
   3. Azevedo VF, et al

   . Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 2017;377:1525-36.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Mease P,
   2. Hall S,
   3. FitzGerald O, et al

   . Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 2017; 377:1537-50.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Mease PJ,
   2. van der Heijde D,
   3. Ritchlin CT, et al

   . Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 2017;76:79-87.

   OpenUrlAbstract/FREE Full Text